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Abstract
Background: The evaluation of patients with abdominal discomfort is challenging and patient selection for
endoscopy based on symptoms is not reliable. We evaluated the diagnostic value of fecal calprotectin in patients
with abdominal discomfort.
Methods: In an observational study, 575 consecutive patients with abdominal discomfort referred for endoscopy
to the Department of Gastroenterology & Hepatology at the University Hospital Basel in Switzerland, were enrolled
in the study. Calprotectin was measured in stool samples collected within 24 hours before the investigation using
an enzyme-linked immunosorbent assay. The presence of a clinically significant finding in the gastrointestinal tract
was the primary endpoint of the study. Final diagnoses were adjudicated blinded to calprotectin values.
Results: Median calprotectin levels were higher in patients with significant findings (N = 212, median 97 μg/g, IQR
43-185) than in patients without (N = 326, 10 μg/g, IQR 10-23, P < 0.001). The area under the receiver operating
characteristics curve (AUC) to identify a significant finding was 0.877 (95% CI, 0.85-0.90). Using 50 μg/g as cut off
yielded a sensitivity of 73% and a specificity of 93% with good positive and negative likelihood ratios (10.8 and
0.29, respectively). Fecal calprotectin was useful as a diagnostic parameter both for findings in the upper intestinal
tract (AUC 0.730, 0.66-0.79) and for the colon (AUC 0.912, 0.88-0.94) with higher diagnostic precision for the latter
(P < 0.001). In patients > 50 years, the diagnostic precision remained unchanged (AUC 0.889 vs. 0.832, P = 0.165).
Conclusion: In patients with abdominal discomfort, fecal calprotectin is a useful non-invasive marker to identify
clinically significant findings of the gastrointestinal tract, irrespective of age.
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Background
Abdominal discomfort is a common cause of consultation
in primary care and gastroenterology departments alike
and presents a clinical challenge even for experienced
physicians [1,2]. Unfortunately, patient selection for endo-
scopy based on symptoms is not reliable [3,4] and a sub-
stantial part of patients with abdominal discomfort will
suffer from any number of non-organic diseases, e.g. func-
tional gastrointestinal disorders [5,6]. Accordingly, in
many patients, endoscopy might not be necessary. The use
of diagnostic criteria, including risk factors for organic dis-
ease may help to select patients for endoscopy [7,8]. How-
ever, the evaluation and risk stratification of this
important group of patients with a non-invasive, and
widely available test is highly desirable.
Over the past years, fecal calprotectin, a cytosolic pro-
tein in neutrophilic granulocytes that correlates well with
neutrophilic infiltration of the intestinal mucosa [9], has
been investigated as biological marker of intestinal
inflammation [10], especially in inflammatory bowel dis-
ease (IBD) [11]. Fecal calprotectin reliably distinguished
IBD from functional gastrointestinal disorder [12,13] and
correlated well with IBD disease activity [14]. Increased
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[15], microscopic colitis [16], bacterial diarrhea [17], after
the use of non-steroidal anti-inflammatory drugs [18], in
peptic ulcer [19], and gastric cancer [20].
The role of fecal calprotectin in unselected patients
with abdominal discomfort referred for diagnostic endo-
scopy has been poorly studied [21]. Specifically, it is not
known whether fecal calprotectin can be used as a diag-
nostic marker of organic gastrointestinal disease. In addi-
tion, it should be further explored and validated whether
the diagnostic ability of calprotectin in the colon can be
expanded to the upper gastrointestinal tract. This has not
been investigated before.
The aim of our study was therefore to prospectively
investigate the value of fecal calprotectin as a biological
marker for the diagnosis of intestinal organic disease in
symptomatic patients. To do so, we investigated consecu-
tive patients with abdominal discomfort referred for
endoscopy.
Methods
Setting and participants
In this observational study, we prospectively investigated
patients undergoing endoscopy of the gastrointestinal
tract for abdominal discomfort at the Department of
Gastroenterology of the University Hospital Basel in
Switzerland. Switzerland has an open-access system for
endoscopy and the decision to perform endoscopy was
based on clinical grounds by the referring physician.
Abdominal discomfort was defined as any sensation of
any quality and intensity of abdominal pain. If several
symptoms were present, abdominal discomfort had to be
the main symptom. A total of 575 patients were enrolled
in two series of consecutive patients: 405 patients with
abdominal discomfort referred for colonoscopy and
another 170 patients referred for esophagogastroduode-
noscopy (EGD). Patients younger than 18 years old were
excluded. The study was carried out according to the
principles of the Declaration of Helsinki and the local
ethic committees of all participating sites approved the
protocol. All patients provided written informed consent
before participating in any protocol-specific procedures.
Endpoint
The presence of a clinically significant finding in the gas-
trointestinal tract was the primary endpoint. For the pur-
pose of this study, a clinically significant finding was
defined by the presence of mucosal inflammation with
mucosal breaks.
Adjudication of the final diagnosis
The final diagnosis was independently adjudicated by two
gastroenterologists not involved in patient care, blinded
to fecal calprotectin values on the basis of all available
medical records pertaining to the individual patient (clin-
ical data, laboratory values, endoscopy report, histology
report) according to current recommendations [22-25].
The physicians adjudicated the final diagnosis by choos-
ing one or more diagnoses from a pre-specified list that
included the following items: Normal findings, esophagi-
tis LA grade A-D, erosive gastritis/duodenitis, gastric/
duodenal ulcer, gastric carcinoma, infectious colitis,
crohn’s disease, ulcerative colitis, ischemic colitis, micro-
scopic colitis, diverticulitis, adenomatous polyp, hyper-
plastic polyp, colorectal cancer, other, or unknown. If
more than one finding was identified, the degree of
mucosal inflammation decided on the final diagnosis.
When there was disagreement about the final diagnosis,
cases were reviewed and adjudicated in conjunction with
a third gastroenterology specialist who was considered an
expert in the field.
Measurement of fecal calprotectin
Calprotectin was measured in a single stool sample in all
patients. Patients were instructed to collect the sample at
home 24 hours prior to bowel preparation for endoscopy.
Samples were delivered on the day of the investigation and
stored in a refrigerator before transfer to the study labora-
tory (Rothen Medical Laboratories, Basel, Switzerland)
within 48 hours for analysis. Calprotectin is stable up to
seven days at room temperature [26].
Fecal calprotectin was determined using a commer-
cially available enzyme-linked immunosorbent assay
(Bühlmann Laboratories AG, Schönenbuch, Switzerland)
that measures quantitative calprotectin. Aliquots of
approximately 100 mg feces were homogenized in 5 mL
extraction buffer. 2 mL of the homogenate was then cen-
trifuged in a microcentrifuge for 5 min at 3000 g and 100
μl of the diluted supernatant (1:50 with incubation buf-
fer) were incubated at room temperature onto a microti-
ter plate coated with a monoclonal capture antibody
highly specific to the calprotectin heterodimeric and
polymeric complexes. After incubation, washing, a sec-
ond incubation with a specific detection antibody, and a
further washing step, tetramethylbenzidine (blue color
formation) followed by a stop solution (change to yellow
color) were added. The absorption was determined at an
optical density of 450 nm. The measuring range of the
test was 10-600 μg calprotectin/g feces with an intra- and
inter-assay coefficient of 4.7% and 4.1%, respectively. The
calprotectin cut-off level representing a positive value
was equal or greater than 50 μg/g as stated by the manu-
facturer. All fecal samples were processed within 72
hours after collection. The laboratory personnel carrying
out the analysis was blinded to the clinical history and
the endoscopic findings of the patients.
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All patients underwent standard endoscopies performed
by 4 senior gastroenterologists who were unaware of fecal
calprotectin values at the time of the investigation. All
endoscopies were documented on a computer-based data-
sheet (ViewPoint, GE Healthcare, Chalfont St Giles, U.K.)
that included a detailed description of the findings by
choosing from a predefined list and electronic storage of
all images taken during the investigation. Biopsies were
collected if appropriate as decided by the endoscopist.
Patients with no significant lesion but elevated fecal cal-
protectin levels (> 50 μg/g) on initial endoscopy were
further investigated with either EGD or colonoscopy. The
endoscopists performing the follow up endoscopy were
aware of the reason for the investigation (positive test).
Statistical analysis
Results of numerical data are presented as mean (standard
deviation, SD) or median (interquartile range, IQR) where
appropriate. The Mann-Whitney U-test (for two indepen-
dent groups) and the Kruskal-Wallis H-test (for more than
two independent groups) were used to compare numerical
data and the chi-square test was used to compare categori-
cal data. Correlations between numerical data were deter-
mined using Pearson or Kendall’s tau correlation
coefficient (r) where appropriate. Receiver operating char-
acteristics analyses were carried out to determine the test
characteristics of fecal calprotectin to identify a clinically
significant finding in the gastrointestinal tract. Test char-
acteristics are presented as sensitivity, specificity, positive
and negative likelihood ratios (LR
+,L R
-), and positive and
negative predictive values (NPV, PPV). Overall accuracy of
the test was calculated according to the following formula:
(true positive test results + true negative test results)/total
population. A p-value smaller than 0.05 was considered to
be statistically significant.
The prevalence of a clinically significant gastrointestinal
lesion in patients with abdominal discomfort was expected
at 35%. We used a nomogram to calculate the sample size
[27]: Estimating a sensitivity of 85% and a confidence
interval of 95% to detect a clinically significant lesion, the
targeted sample size was 500 patients.
Results
Patients Characteristics
Of 575 patients enrolled in the study, 538 (94%, 248 male,
290 female) were included in the final analysis (Figure 1).
Thirty-seven patients (6.4%) were excluded; 6 patients for
incomplete endoscopy and 31 patients because they did
not complete the diagnostic work up as required by the
protocol. Baseline characteristics are shown in Table 1.
Overall, 457 colonoscopies (85% of all patients) and 217
EGDs (40%) were performed. Fifteen patients received
capsule endoscopy but none revealed significant findings.
Clinically significant lesions in patients with abdominal
discomfort
Among the study population, the prevalence of a signifi-
cant finding was 39%. It was higher in patients initially
investigated with EGD (47%) than with colonoscopy (37%,
P = 0.028). In a majority of patients, endoscopy revealed
normal findings (N = 314, 58%). Median calprotectin levels
were higher in patients with significant findings (N = 212,
median 97 μg/g, IQR 43-185 μg/g) than in patients with-
out (N = 326, 10 μg/g, IQR 10-23, P < 0.001). Table 2 lists
adjudicated final diagnoses and respective median values
of calprotectin.
Diagnostic value of fecal calprotectin to detect organic
disease of the gastrointestinal tract
Evaluating the value of fecal calprotectin as a diagnostic test
to identify significant gastrointestinal findings at endoscopy,
we found an area under the receiver operating characteris-
tics curve (AUC) of 0.877 (95% CI, 0.85-0.90, Figure 2A)
with an optimal cut-off at 50 μg/g. Using this cut-off
yielded a sensitivity of 73% and a specificity of 93% with
positive and negative likelihood ratios of 10.8 and 0.29,
respectively (Table 3). Fecal calprotectin levels < 10 μg/g
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Figure 1 Study flow. Study flow of patients referred for colonoscopy
and esophagogastroduodenoscopy (EGD). A total of 37 patients were
excluded from the final analysis, in 29 patients because follow-up
endoscopy was not performed as required by the protocol (no clinically
significant lesion on endoscopy but fecal calprotectin > 50 μg/g)
Table 1 Baseline Characteristics
Referred for
colonoscopy
Referred for EGD Total
Number of patients 391 147 538
Female patients, N (%) 218 (56%) 72 (49%) 290 (54%)
Age, years 63 (53-71) 55 (42-65) 60 (49-70)
Colonoscopy, N (%) 391 (100%) 66 (45%) 457 (85%)
EGD, N (%) 70 (18%) 147 (100%) 217 (40%)
Data are presented as median (interquartile range) and number of patients
(%). EGD: esophagogastroduodenoscopy.
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Page 3 of 9indicated that it was very unlikely (sensitivity 94%, LR
+ 1.9,
LR
- 0.12) to detect a significant lesion at endoscopy, given
the high negative predictive value of 93%. The overall accu-
racy of the test was 85% and 68% using a cut-off of 50 μg/g
and 10 μg/g, respectively (Figure 3). Among patients with
false negative test results when using 10 μg/g as cut-off
were 5 patients with esophagitis LA grade A, 4 patients
with colorectal adenoma, and 1 patient with each with col-
orectal carcinoma of the sigma, gastric ulcer, erosive gastri-
tis, and diverticulitis.
Fecal calprotectin to identify upper gastrointestinal
disease
As a diagnostic test to identify significant findings in the
upper gastrointestinal tract, fecal calprotectin showed an
area under the receiver operating characteristics curve of
0.730 (95% CI 0.66-0.79). At the optimal cut-off (48 μg/g),
fecal calprotectin provided 60% sensitivity and 81% specifi-
city with positive and negative likelihood ratios of 3.23 and
0.50, respectively. The diagnostic ability of fecal calprotec-
tin in the upper intestinal tract was less performant com-
pared to the colon (AUC 0.912, 95% CI 0.88-0.94, P <
0.001, Figure 2, Table 3).
Interestingly, in patients with gastric mucosal lesions,
fecal calprotectin values increased with disease severity
(Figure 4). Values in patients with normal endoscopic find-
ings on EGD (18 μg/g, IQR 10-37) were lower than in
patients with erosive gastritis (70 μg/g, IQR 27-156, P <
0.001), peptic ulcers (125 μg/g, IQR 66-125, P < 0.001),
and gastric carcinoma (355 μg/g, IQR 188-881, P = 0.002).
Diagnostic value of calprotectin in patients at higher risk
for organic disease
Patients older than 50 years (384 patients, 71%) were
not more likely to present a significant finding on endo-
scopy (42% vs 33%, P = 0.07). When analyzed according
to age, the diagnostic ability of fecal calprotectin was
similar in patients younger than 50 years (AUC 0.832,
95%CI 0.76-0.89) and in patients older than 50 years
(AUC 0.889, 95%CI 0.85-0.92, P = 0.165). The overall
accuracy of the test was 83% and 86%, respectively.
Among patients with normal findings on endoscopy
(314 patients, 58%), older patient groups (divided by
decades of age) did not have higher median calprotectin
values and no correlation existed between increasing age
and calprotectin levels (R = -0.02, P = 0.709).
Table 2 Final diagnoses and fecal calprotectin values
Final diagnosis N Median IQR
No Clinically Significant Finding 326 10 10 - 23
Normal findings 314 10 10 - 22
Hyperplastic polyps 12 34 22 - 62
Clinically Significant Finding 212 97 43 - 185
Esophagitis 31 103 60 - 170
Esophagitis LA grade A 25 17 11 - 29
Esophagitis LA grade B 10 167 59 - 205
Esophagitis LA grade C 9 125 62 - 163
Esophagitis LA grade D 12 85 66 - 136
Erosive gastritis/duodenitis 22 70 27 - 156
Gastric ulcers 11 125 66 - 214
Gastric carcinomas 3 355 188 - 881
Colitis/Ileitis 53 152 85 - 338
Infectious Colitis 8 127 71 - 1317
Crohn’s disease 10 69 54 - 145
Ulcerative colitis 16 152 90 - 281
Diverticulitis 13 260 145 - 537
Microscopic colitis 5 281 239 - 410
Ischemic colitis 1 314 -
Adenomatous polyps 50 101 25 - 170
Colorectal cancers 17 104 82 - 295
Data are presented as median with interquartile range (IQR).
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Figure 2 Receiver Operating Characteristics Curve. To identify clinically significant findings in the gastrointestinal tract, fecal calprotectin had
an area under the receiver operating characteristics (ROC) curve of 0.877 (95% CI 0.85-0.90) (Figure 2A). The AUC of fecal calprotectin to identify
clinically significant findings was better in the lower intestinal tract (AUC 0.912, 95%CI 0.88-0.94) (Figure 2C) than in the upper intestinal tract
(AUC 0.730, 95%CI 0.66-0-79, P < 0.001) (Figure 2B).
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Page 4 of 9Table 3 Test characteristics of fecal calprotectin to predict a clinically significant gastrointestinal finding
Clinically significant finding AUC (95%CI) Cut-off (μg/g) Sens
(%)
Spec
(%)
LR+ LR- NPV (%) PPV (%) Accuracy (%)
Overall 0.877 (0.85 - 0.90) 50 73 93 10.8 0.29 88 84 85
Upper gastrointestinal tract 0.730 (0.66 - 0.79) 48 59 82 3.2 0.50 75 68 71
Lower gastrointestinal tract 0.912 (0.88 - 0.94) 50 84 92 10.6 0.17 82 93 89
Area under the receiver operating characteristics curve (AUC) with corresponding sensitivity (Sens), specificity (Spec), positive and negative likelihood ratio (LR+,
LR-), and negative and positive predictive values (NPV, PPV) for fecal calprotectin to identify a clinically significant finding in the gastrointestinal tract. Overall
accuracy was calculated using the following formula: (true positive test results + true negative test results)/total population.
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Figure 3 Diagnostic accuracy of fecal calprotectin. The overall test accuracy of fecal calprotectin was 85% when 50 μg/g was used as cut off
value (upper panel) and was 68% when 10 μg/g was used (lower panel).
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Page 5 of 9Diagnostic value of calprotectin in patients with negative
initial endoscopy
One hundred and thirty-six patients (25%) were investi-
gated with both EGD and colonoscopy; 74 patients (54%)
had EGD first and 62 (46%) had colonoscopy first. In 38
patients (28%), both procedures were done on the same
day for clinical reasons and in 98 patients (82%), follow-up
endoscopy was done after no clinically significant findings
had been identified during the initial investigation. The
median time to follow-up endoscopies was 11 days.
Follow-up investigations (51 EGDs and 47 colonoscopies)
resulted in 44 additional findings, including 2 colorectal
carcinomas, 6 colorectal adenomas, 1 crohn’s disease, 1
ulcerative colitis, and 5 peptic ulcers. Patients with signifi-
cant lesions on follow-up endoscopy had higher median
calprotectin levels (139 μg/g (IQR 57-190) vs 40 μg/g (IQR
10-162), P = 0.008) and accordingly, were more likely to
have abnormal calprotectin test results (57% vs 43%, P =
0.003). In 10 patients (26%), test results were falsely nega-
tive. The overall test accuracy of fecal calprotectin was
63%.
Discussion
This prospective study in a large cohort of patients exam-
ined the use of calprotectin measurement in feces as a
diagnostic test to identify clinically significant gastroin-
testinal findings in patients with abdominal discomfort
referred for endoscopy. We provide the following new
information: Patients with clinically significant findings at
endoscopy had higher fecal calprotectin values than
patients without; fecal calprotectin measured before
endoscopy reliably predicted the presence of significant
findings throughout the gastrointestinal tract; fecal cal-
protectin provided valuable diagnostic ability for signifi-
cant findings in the upper intestinal tract but performed
less well compared to findings in the colon; the diagnos-
tic performance was independent of age > 50 years, an
important risk factor for organic disease; and calprotectin
levels indicated disease severity in patients with mucosal
lesions of the stomach.
These findings are of clinical importance as they encou-
rage the use of this simple and easily available biomarker
in the diagnostic approach to patients with abdominal dis-
comfort, especially to decide upon the necessity to per-
form endoscopy. Patients with fecal calprotectin levels >
50 μg/g should receive either esophagogastroduodeno-
scopy (EGD) or colonoscopy according to clinical presen-
tation and if negative, follow-up endoscopy, as the
prevalence of significant findings with negative initial
endoscopy reached 57% in these patients.
Over the last decade, the number of endoscopies per-
formed by gastroenterologists has steadily increased both
i nt h eU S Aa n di nE u r o p e[ 2 8 , 2 9 ] .G i v e nt h el i m i t e d
resources and ever increasing health-care costs, optimiz-
ing the appropriate selection of patients for endoscopy is
crucial. Unfortunately, selection based on symptoms is
not reliable; even when compared to an expert panel,
individual gastroenterologists tend to overestimate the
appropriateness of endoscopies they perform [30]. The
Danish Dyspepsia Group found clinical diagnosis of epi-
gastric pain for more than two weeks unreliable and half
of all patients with peptic ulcer or reflux esophagitis were
misclassified [3]. In another study, neither age nor the
presence of alarm features were effective predictors of
endoscopic findings in patients with upper abdominal
pain [31]. The diagnostic yield of colonoscopy in patients
with symptoms other than bleeding or diarrhea was
shown to be equal to a screening population [32] and
average risk patients with non-specific abdominal symp-
toms have similar rates of adenomatous polyps as asymp-
tomatic patients [33,34]. Both the American Society for
Gastroenterological Endoscopy (ASGE) and the European
Panel on the Appropriateness of Gastrointestinal Endo-
scopy (EPAGE) have released guidelines in an attempt to
optimize patients selection for endoscopy [35-37]. Apply-
ing these guidelines yielded significantly more findings
for appropriate than for inappropriate endoscopies, but
the selection criteria suffered from low specificity [38,39].
Calprotectin is a calcium binding protein of neutrophil
granulocytes that correlates well with neutrophil infiltra-
tion of the intestinal mucosa when measured in feces,
has antimicrobial activity, and is resistant to enzymatic
degradation both in vivo and in vitro [9,40]. Accordingly,
as a marker of neutrophilic intestinal inflammation, cal-
protectin values might reflect a composite endpoint for
Figure 4 Fecal calprotectin and severity of mucosal damage.
Boxplots (median, 25
th and 75
th percentile) of fecal calprotectin
values in patients with normal endoscopic findings (normal), gastric
erosions (erosion), gastric ulcer (ulcer), and gastric cancer
(carcinoma). * P < 0.001 against normal, # P = 0.002 against normal,
§ P = 0.157 against ulcer, † P = 0.027 against carcinoma, $ P =
0.088 against carcinoma.
Manz et al. BMC Gastroenterology 2012, 12:5
http://www.biomedcentral.com/1471-230X/12/5
Page 6 of 9organic intestinal disease. In fact, a mean sensitivity and
specificity of 83% and 84%, respectively, has been
reported for calprotectin to distinguish organic from
non-organic disorders in patients with abdominal dis-
comfort [12]. To separate IBD from non-IBD, the diag-
nostic accuracy is even higher. Mean sensitivity and
specificity was 93% and 96%, respectively, in a recent
meta-analysis [11]. Altogether, those studies suggest that
elevated fecal calprotectin levels reflect the presence of
mucosal inflammation and thus may be used to detect
o r g a n i cd i s e a s eo ft h eg a s t r o i n testinal tract, especially in
symptomatic patients.
The value of fecal calprotectin in consecutive patients
referred for endoscopy has been poorly studied. In an
Italian study, fecal calprotectin was measured in conse-
cutive unselected outpatients undergoing colonoscopy
and was found to be elevated in a majority of patients
with colorectal cancer and inflammatory conditions of
the colon but also in 36% patients with normal endo-
scopic findings [21]. The negative predictive of fecal cal-
protectin was 96%.
Our study measured fecal calprotectin in 538 consecu-
tive patients with abdominal discomfort referred for
endoscopy. We found that fecal calprotectin was highly
useful in the assessment of this important group of
patients as it reliably distinguished patients with clini-
cally significant gastrointestinal findings from patients
without. Therefore, we confirm findings of prior studies
[10-13], but expand the results obtained in these specific
patient groups to an unselected group of consecutive
patients with abdominal discomfort. It is a remarkable
strength of this study that we did not investigate
selected patients or patient groups with high clinical
suspicion for a specific disorder. In our study, fecal cal-
protectin provided valuable diagnostic assistance in a
heterogeneous patient population. Accordingly, our
results favor measurement of fecal calprotectin prior to
endoscopic investigation of patients with abdominal
discomfort.
Our study further showed that fecal calprotectin had
good diagnostic ability also in patients with significant
findings of the upper intestinal tract. Previously, elevated
fecal calprotectin values have been reported in peptic
ulcer disease and gastric cancer [19,20] but the diagnos-
tic value in consecutive patients referred for EGD has
never been systematically examined. We found calpro-
tectin to be a valuable biomarker in the evaluation of
upper abdominal discomfort; especially when consider-
ing the initial clinical approach to these patients is still
open to debate. Currently, prompt endoscopy is usually
recommended to evaluate new onset dyspepsia for
patients over 45 years or with alarm features to rule out
malignancy [41], but using these criteria, the high sensi-
tivity to detect relevant findings or new malignancies
(82% and 97%) was substantially impaired by low speci-
ficity (26% and 20%) [42]. In our study, using fecal cal-
protectin gave a lower sensitivity (59%) but provided a
much higher specificity (84%).
Fecal calprotectin values of patients with esophagitis
LA grade A (mucosal breaks < 5 mm, limited to a single
mucosal fold) were similar than in patients with normal
findings (Table 2). This finding merits special considera-
tion. In the LA system, grading of esophagitis has been
limited to erosions in an attempt to increase inter-
observer agreement. However, for esophagitis grade A,
considerable inter-observer variability has been
described (kappa value 0.167) [43]. Endoscopic grading
of esophageal erosions is far from perfect, especially for
smaller lesions, and this might have contributed to the
low sensitivity of fecal calprotectin to detect espohagitis
grade A. The impaired sensitivity should be recognized
and integrated in the clinical evaluation of patients with
abdominal discomfort, especially in the presence of con-
comitant reflux symptoms.
The diagnostic precision was uniformly high, both in
younger patients (age < 50 years) with a low pretest prob-
ability, and older patients at higher risk for organic
intestinal disease. We also cannot confirm that fecal cal-
protectin values increase with age in patients with normal
findings on endoscopy, as suggested from data in healthy
volunteers [44].
All together, those results support the concept that
fecal calprotectin is a useful marker in the evaluation of
patients with abdominal discomfort and that a biomar-
ker-guided strategy might have additional value to a
strategy using clinical decision, including guidelines of
appropriateness, to decide on endoscopy. It is important
to recognize that these results apply only to symptomatic
patients with abdominal discomfort. Especially screening
endoscopies such as colonoscopy should be performed
irrespective of calprotectin values. Fecal calprotectin has
not been established as screening tool for colorectal can-
cer in asymptomatic patients.
Several limitations of the study merit consideration.
First, our prospectively defined endpoint was the pre-
sence of a clinically significant finding. Indeed, classifica-
tion of findings in clinical practice is challenging and
endoscopic findings might not always be congruent with
abdominal discomfort presented by the patient. Second,
in several important gastrointestinal disorders, such as
small bowel bacterial overgrowth, celiac disease, or food
lactose intolerance, fecal calprotectin levels will be nor-
mal [45,46]. Third, we did not systematically assess the
presence of mucosal lesions in the small-bowel. We
acknowledge, that this is a limitation of our study as
increased fecal calprotectin has been shown in small-
bowel enteropathy [47]. In the 15 patients who had small
bowel capsule endoscopy no significant lesion were
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tectin values in expectorations of patients with acute and
chronic pulmonary disease [48]. This might have influ-
enced fecal measurement of calprotectin.
Conclusion
In conclusion, our study showed that fecal calprotectin
values are elevated in patients with organic gastrointest-
inal disease. We confirmed results of previous studies
showing excellent ability of fecal calprotectin to identify
mucosal lesions in the colon. Additionally, we expanded
the role of fecal calprotectin as a diagnostic test to the
upper intestinal tract by demonstrating its ability to iden-
tify esophageal and gastric mucosal lesions. Further pro-
spective studies directly comparing recommended
guidelines of appropriateness for endoscopy with fecal
calprotectin measurements are warranted to establish the
value of a biomarker-guided assessment of patients with
abdominal discomfort and to explore the cost-effective-
ness of such an approach.
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